Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
Abstract Objective The treatment of biliary tract (BTC) cancer remains relatively limited, especially in the setting of advanced BTC. Immune checkpoint inhibitors (ICIs) have shown some effects in a variety of solid tumors, but their efficacy and safety in patients with advanced BTC are still elusiv...
Main Authors: | Zhengfeng Zhang, Dazhen Wang, Liu Yang, Lu Zhao, Lei Yang, Jianji Zhang, Changjie Lou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6209 |
Similar Items
-
Chemotherapy for Biliary Tract Cancer in 2021
by: Takashi Sasaki, et al.
Published: (2021-07-01) -
Editorial: Advances in immunotherapy and combination therapy for biliary tract cancers
by: Chengpei Zhu, et al.
Published: (2024-01-01) -
Current progress in perioperative chemotherapy for biliary tract cancer
by: Tatsuya Ioka, et al.
Published: (2023-07-01) -
Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review
by: Yaoqun Wang, et al.
Published: (2023-04-01) -
FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy
by: Nicolas Roussot, et al.
Published: (2023-11-01)